New National Biosecurity Centre in Harlow aims to fight pandemics
The government said the UKHSA would continue operating from Colindale in north-west London and Porton Down in Wiltshire until the new centre in Harlow was fully up and running, to ensure a safe and effective transition.
About 1,600 jobs will be created to support construction of the Harlow site and it would enable closer collaboration between scientists, the government said.The first facilities are expected to open by the mid-2030s with the site fully operational by 2038."Harlow will become a scientific hub, with the National Biosecurity Centre exploring new ways to treat illnesses, improve people's health and save more lives," said Streeting."By backing innovation, research and life sciences, we will make our NHS fit for the future, and cement the UK as a life sciences superpower."The government said "of the total multi-billion investment in the centre, £250m will be spent by the government over this Parliament alone to kickstart delivery". "The exact total amount of funding for the centre will be confirmed in due course," a spokesperson added.
It was hoped the NBC would create partnerships between scientists in the industry and the UK Health Security Agency (UKHSA) to pursue new breakthroughs.The Harlow site would have laboratories that would be used to study dangerous and new diseases.Dyfed Alsop, interim UKHSA chief executive, said: "This is fantastic news for the UK and will mean that we can continue to offer the best possible protection for people's health for generations to come."The announcement follows a government pledge to spend £1bn upgrading a centre that researches animal diseases in Weybridge, Surrey.The Defence, Science and Technology Laboratory site at Porton Down was not affected by this new development and would remain operational.
Follow Essex news on BBC Sounds, Facebook, Instagram and X.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South Wales Argus
2 hours ago
- South Wales Argus
Weight-loss jabs could help obese people control asthma, study suggests
The drugs should be explored as a potential treatment for obese people with the respiratory condition, who are 'often resistant' to steroids, researchers said. Weight-loss jabs, also known as glucagon-like peptide1 receptor-agonists (GLP1-RAs), work by mimicing the hormone GLP-1 to regulate blood sugar and insulin levels. They were initially developed as a treatment for people with type 2 diabetes. A number of types of the drug are recommended to help tackle obesity on the NHS, including semaglutide, or Wegovy, and tirzepatide, or Mounjaro. Previous studies have suggested the drugs may slash the risk of illnesses like dementia and stroke, with an international team of experts exploring their potential impact on obese people with asthma. Professor David Price, University of Aberdeen chair in primary care respiratory medicine, said: 'People with obesity and asthma are unique in that they are often resistant to steroid treatments. 'We know that GLP1s work on inflammatory responses in the airways in a different way to traditionally used steroids.' For the study, published in Advances in Therapy, researchers analysed the records of 10,111 people on GLP1-RAs and 50,555 people who were not on the drugs. After a follow-up period, the team found that those taking weight-loss jabs lost more weight and had improved asthma control. Researchers said the findings suggest medics 'should pay attention to the relationship between GLP-1 RA and the risk of respiratory diseases'. Prof Price added: 'We found compelling evidence that GLP1s, as well as increasing weight loss, also improved asthma symptoms. 'In addition, it is important to note that the benefits to asthma symptoms occurred despite fairly modest weight loss of around 0.9kg over the course of the year. 'Our findings suggest that GLP1s may have beneficial effects on asthma control for people with obesity and this should be explored further.' Prof Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, said: 'Our findings suggest that GLP1-RAs have benefits on asthma control in people with obesity, and this information should contribute to the discussions around the decision to use these drugs.' Dr Erika Kennington, head of research and innovation at Asthma and Lung UK, said: 'Research has previously shown that people living with obesity who lose weight see improved control of their asthma, so it's encouraging to see this study show this is still the case when the weight loss is driven by drugs, like the new class of weight loss drugs. 'Although exercise can help people lose weight, for some people it can cause anxiety about becoming breathless or having an asthma attack, so people are stuck in a vicious cycle of not being able to lose weight and their asthma worsening. 'Therefore, where exercise hasn't worked for someone these drugs that support weight loss could offer a promising alternative. 'It's too early to say whether these drugs would be effective for people with asthma more widely. 'More research is needed to understand how these drugs actually improve asthma control. Funding for lung health research is on life support and urgent action is needed to increase investment.'
Daily Mail
3 hours ago
- Daily Mail
I'm a doctor - this one household feature is slowly harming your health
A common household feature may be unknowingly creating an unseen health risk – and it's hiding in plain sight. According to GP Dr Emily Carter, older carpets pose an unexpected health threat. 'People usually think of carpets as harmless,' said Dr Carter. 'But old carpets can be a major source of indoor pollution.' Carpets are known to trap allergens like dust mites, pet dander, pollen, mould spores, and even chemical residues from cleaning products or smoke. Over time, these build up in the fibres and can trigger or worsen health issues especially in children, the elderly, and those with asthma or allergies. The difficulty is that this build-up can occur gradually - even when older carpet is regularly vacuumed or appears clean. There are certain recurring health symptoms to be on the look out for that may indicate that your home environment could be be impacting on your health. Signs include frequent sneezing, coughing, or itchy eyes while indoors, worsening allergy or asthma symptoms. Feeling tired or headachy without clear cause is another indicator. Sudden skin irritations - especially in younger children – can also result from carpet-trapped allergens. However, the tricky part with many of these symptoms is that many may be mistaken for seasonal allergies or minor colds. Dr Carter, who is also a UK-based mother of two young children, said she had seen first-hand the health issues that can be caused by older carpets. 'I've seen it in my own family, my youngest started getting skin rashes and breathing problems that we couldn't explain,' Dr Carter said. 'After having our carpets replaced and testing air quality, the symptoms started improving.' For anyone who is concerned about whether their carpet poses a possible health risk, the British doctor recommends a simple 'sniff test' as a first line assessment. 'If a room smells musty no matter how often you clean it, that's a red flag,' Dr Carter said. 'Especially in bedrooms, where people spend hours each night, clean air matters more than we think.' For families with babies, Dr Carter also urges extra caution: 'Young children spend a lot of time crawling and playing on floors.' 'Their immune systems are still developing, so they're more likely to react to mould spores and dust mites. If you notice frequent eczema flare-ups or a child often gets congested indoors, your flooring could be part of the problem.' According to My Home Improvements, most carpets should be replaced every 7–10 years, depending on usage, cleaning habits, and exposure to pets or dampness. The UK home renovation business suggests that any carpet over a decade old is likely to be 'past its best'. 'Your carpet is like a sponge, it absorbs everything that enters your home. Over time, it collects years of grime, allergens, and chemical residues that vacuuming can't always reach,' says an expert from My Home Improvements. 'Even professional deep cleans won't remove built-up toxins that have soaked into the padding underneath. 'Replacing old flooring might not be glamorous, but it could be the biggest upgrade you make for your health.'
Rhyl Journal
3 hours ago
- Rhyl Journal
Weight-loss jabs could help obese people control asthma, study suggests
The drugs should be explored as a potential treatment for obese people with the respiratory condition, who are 'often resistant' to steroids, researchers said. Weight-loss jabs, also known as glucagon-like peptide1 receptor-agonists (GLP1-RAs), work by mimicing the hormone GLP-1 to regulate blood sugar and insulin levels. They were initially developed as a treatment for people with type 2 diabetes. A number of types of the drug are recommended to help tackle obesity on the NHS, including semaglutide, or Wegovy, and tirzepatide, or Mounjaro. Previous studies have suggested the drugs may slash the risk of illnesses like dementia and stroke, with an international team of experts exploring their potential impact on obese people with asthma. Professor David Price, University of Aberdeen chair in primary care respiratory medicine, said: 'People with obesity and asthma are unique in that they are often resistant to steroid treatments. 'We know that GLP1s work on inflammatory responses in the airways in a different way to traditionally used steroids.' For the study, published in Advances in Therapy, researchers analysed the records of 10,111 people on GLP1-RAs and 50,555 people who were not on the drugs. After a follow-up period, the team found that those taking weight-loss jabs lost more weight and had improved asthma control. Researchers said the findings suggest medics 'should pay attention to the relationship between GLP-1 RA and the risk of respiratory diseases'. Prof Price added: 'We found compelling evidence that GLP1s, as well as increasing weight loss, also improved asthma symptoms. 'In addition, it is important to note that the benefits to asthma symptoms occurred despite fairly modest weight loss of around 0.9kg over the course of the year. 'Our findings suggest that GLP1s may have beneficial effects on asthma control for people with obesity and this should be explored further.' Prof Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, said: 'Our findings suggest that GLP1-RAs have benefits on asthma control in people with obesity, and this information should contribute to the discussions around the decision to use these drugs.' Dr Erika Kennington, head of research and innovation at Asthma and Lung UK, said: 'Research has previously shown that people living with obesity who lose weight see improved control of their asthma, so it's encouraging to see this study show this is still the case when the weight loss is driven by drugs, like the new class of weight loss drugs. 'Although exercise can help people lose weight, for some people it can cause anxiety about becoming breathless or having an asthma attack, so people are stuck in a vicious cycle of not being able to lose weight and their asthma worsening. 'Therefore, where exercise hasn't worked for someone these drugs that support weight loss could offer a promising alternative. 'It's too early to say whether these drugs would be effective for people with asthma more widely. 'More research is needed to understand how these drugs actually improve asthma control. Funding for lung health research is on life support and urgent action is needed to increase investment.'
